Ultragenyx Pharmaceutical Inc
(FRA:UP0)
€
46
-0.2 (-0.43%)
Market Cap: 4.37 Bil
Enterprise Value: 3.82 Bil
PE Ratio: 0
PB Ratio: 13.49
GF Score: 79/100 Ultragenyx Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023 / 02:45PM GMT
Release Date Price:
€37
(+4.52%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Right. Good morning, and thank you for joining us -- I think Fifth Annual Guggenheim Genomic Medicines on Rare Disease Conference. I'm Debjit and my privilege to host Emil Kakkis, the CEO of Ultragenyx.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Thank you.
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Thank you, Emil, for being here. It's going to be a pretty interesting second half for you guys.
Questions & Answers
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
So maybe we can start with the upcoming catalysts and where the pipeline currently stands?
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Sure. We will
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot